Ken Griffin Sage Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$7.02 - $13.08 $150,930 - $281,220	-21,500 Reduced 56.14%	16,800 $121,000
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $174,570 - $295,350	16,500 Added 75.69%	38,300 $415,000
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $232,750 - $336,875	-12,500 Reduced 36.44%	21,800 $408,000
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $653,220 - $850,332	-38,200 Reduced 52.69%	34,300 $743,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $552,750 - $1.62 Million	33,000 Added 83.54%	72,500 $1.49 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $792,675 - $1.16 Million	19,500 Added 97.5%	39,500 $1.86 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $611,228 - $763,748	-16,400 Reduced 45.05%	20,000 $839,000
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $202,860 - $274,743	6,300 Added 20.93%	36,400 $1.39 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $671,424 - $900,016	-20,800 Reduced 40.86%	30,100 $1.18 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.